1 Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are highly efficacious in patients with type 2 diabetes (T2D) [1-5], chronic kidney disease [6, 7], and heart failure [8-11]; yet, their use in patients with type 1 diabetes (T1D) has been limited due to increased risk of diabetic ketoacidosis (DKA) despite demonstrated benefits for glycaemic control [12-15].
Get in touch with Rosa
Contact Rosa, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack